{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:56:04Z","timestamp":1787064964910,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1093\/jac\/dkx423","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T23:15:44Z","timestamp":1508800544000},"page":"757-763","source":"Crossref","is-referenced-by-count":51,"title":["Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial"],"prefix":"10.1093","volume":"73","author":[{"given":"Dimitrios P","family":"Kontoyiannis","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[{"name":"AZ Sint Jan Brugge Oostende AV, Brugge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Mullane","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Section of Infectious Diseases, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Clinical Trials Centre, University of Cologne (ZKS K\u00f6ln), Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Centre d\u2019Infectiologie Necker Pasteur, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Croos-Dabrera","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lademacher","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F","family":"Patterson","sequence":"additional","affiliation":[{"name":"Infectious Disease, UT Health San Antonio and the South Texas Veterans Health Care System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"key\n\t\t\t\t20180216030014_dkx423-B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1987.5.12.1985","article-title":"Favorable outcome of invasive aspergillosis in patients with acute leukemia","volume":"5","author":"Burch","year":"1987","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1469-0691.2008.02122.x","article-title":"Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis","volume":"15","author":"Cordonnier","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors associated with mortality in transplant patients with invasive aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.21488","article-title":"Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes","volume":"84","author":"Parody","year":"2009","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B15","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1128\/IAI.00909-06","article-title":"Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus conidia","volume":"74","author":"Bonnett","year":"2006","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B16","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.4049\/jimmunol.178.10.6367","article-title":"Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion","volume":"178","author":"Zarember","year":"2007","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bmt.2009.39","article-title":"Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients","volume":"44","author":"Mikulska","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/00365540902856529","article-title":"Prognostic factors for invasive aspergillosis in patients with haematological malignancies","volume":"41","author":"Reuter","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/AAC.00662-11","article-title":"Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic\/pharmacodynamic model","volume":"56","author":"Meletiadis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: a new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Ananda-Rajah","year":"2015","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.24022","article-title":"Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients","volume":"115","author":"Maertens","year":"2009","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1439-0507.2010.02009.x","article-title":"Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients","volume":"54","author":"Park","year":"2011","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B25","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications","volume":"46","author":"Miceli","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.22863","article-title":"Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer","volume":"110","author":"Woods","year":"2007","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B27","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cid\/cix198","article-title":"Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response","volume":"64","author":"Kovanda","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/597400","article-title":"Phaeohyphomycosis in a tertiary care cancer center","volume":"48","author":"Ben-Ami","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180216030014_dkx423-B31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/3\/757\/23823562\/dkx423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T03:00:22Z","timestamp":1518750022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/3\/757\/4675068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,11,29]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx423","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2017,11,29]]}}}